Total Reports
24
FDA CVM filings
Dog /
2026 FDA CVM data 24 reports on file official source
Kuvasz — FDA Adverse Event Profile
Adverse-event records and label data for Kuvasz (Dog), sourced from the FDA Center for Veterinary Medicine. Refreshed as new reports are filed. Cite PlainBreed when reusing this analysis.
Kuvasz (Dog) has 24 FDA adverse event reports on record, with 2 deaths reported (830.0% death rate) — ranking #342 by report volume. The most frequently reported reaction is Vomiting (5 cases). The top associated drug is Fluralaner Chew Tablets. Average age at report: 6.4 years.
Deaths Reported
2
of 24 reports
Death Rate
830.0%
death-coded share
Avg Age at Report
6.4 yr
41.1 kg avg weight
Death-Coded Outcome Share
Kuvasz death-coded reports 100.0%
Database median
830.0% of 24 reports involved a death outcome. Read alongside breed popularity, veterinary access, and owner awareness — these shape how many events ever reach the FDA. The 12% comparison line is the rough cross-breed median in the FDA CVM database; values above suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Average weight at time of report: 41.1 kg (90.6 lbs)
Top Reported Reactions
Vomiting 5
Other abnormal test result NOS 5
Anorexia 4
Lack of efficacy (endoparasite) - heartworm 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Weakness 3
Elevated blood urea nitrogen (BUN) 3
Elevated creatinine 3
Decreased packed cell volume (PCV) 3
Polydipsia 2
Neutrophilia 2
Weight loss 2
Decreased red blood cell count 2
Lack of efficacy - NOS 2
INEFFECTIVE, HEARTWORM LARVAE 2
Most Referenced Drugs
Fluralaner Chew Tablets 4
Milbemycin Oxime + Spinosad 3
Trilostane 2
Moxidectin 2
Carprofen 2
Fenbendazol Granules 2
Ivermectin + Pyrantel 2
Ivermectin + Pyrantel As Pamoate Salt 2
Cyclosporine 1
Glycosaminoglycan Polysulfate 1
Fluoxetine 1
Firocoxib 227 Mg Chewable 1
Ivermectin/Pyrantel Pamoate Chewable 272Mcg/652Mg 1
Polysulfated Glycosaminoglycan 1
Gabapentin 1
Outcome Breakdown
Ongoing
9 (42.9%)
Outcome Unknown
5 (23.8%)
Recovered/Normal
3 (14.3%)
Euthanized
2 (9.5%)
Recovered with Sequela
2 (9.5%)
Gender Distribution
Female 12 (50.0%)
Male 12 (50.0%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2010 | 3 | |
| 2012 | 1 | |
| 2013 | 3 | |
| 2014 | 3 | |
| 2015 | 2 | |
| 2016 | 3 | |
| 2017 | 2 | |
| 2019 | 1 | |
| 2020 | 4 | |
| 2023 | 1 | |
| 2024 | 1 | |
Kuvasz Pet Health Insights
Across the FDA Center for Veterinary Medicine adverse event database, Kuvasz accounts for 24 submitted reports and currently ranks #342 by report volume within the dog population. Of those reports, 2 involved a death outcome — a 830.0% case-fatality figure calculated directly from the underlying FDA records rather than from external mortality studies. The mean age at time of reporting is 6.4 years, with an average recorded body weight of 41.1 kg (90.6 lbs). These figures reflect the voluntary reporting pool only and should be read alongside breed popularity, veterinary access, and owner awareness — all of which shape how many events ever reach the FDA.
The most frequently reported clinical signs for Kuvasz are Vomiting (5 reports), Other abnormal test result NOS (5 reports), Anorexia (4 reports), together capturing a substantial share of the top-reaction traffic seen in this breed's record. On the product side, Fluralaner Chew Tablets appears in 4 reports and is the single most-referenced drug, followed by Milbemycin Oxime + Spinosad (3) and Trilostane (2). Counts like these surface which therapeutic classes dominate the reporting stream — useful context when comparing reactions across breeds of the same dog species.
Outcome coding on the 21 reports with a recorded status is dominated by Ongoing (42.9% of coded outcomes). Annual submission volume ranges from 2,010 to 2,024 reports across the 11 years on file, indicating the reporting trend is shaped as much by awareness cycles as by underlying clinical events. Because FDA adverse event reports describe correlation rather than causation, these numbers are most useful as a signal of where to ask further questions with a veterinarian — not as a standalone risk score for any individual dog.
Understanding Kuvasz Adverse Event Data
Kuvasz has 24 adverse event reports on file. Lower report volumes may reflect a less common breed, lower reporting rates, or genuinely fewer adverse events.
The 830.0% death rate is above average, though this statistic should be interpreted cautiously. Death reports may be overrepresented because serious outcomes are more likely to be reported than mild reactions.
The most frequently referenced drug in adverse reports is Fluralaner Chew Tablets, appearing in 4 reports. This may indicate widespread use of the medication rather than a specific safety concern for Kuvasz.
Other Dog Breeds
Retriever - Labrador
90,806 reports · 360.0% death rate
Crossbred Canine/dog
68,210 reports · 320.0% death rate
Dog (unknown)
47,381 reports · 870.0% death rate
Retriever - Golden
34,475 reports · 370.0% death rate
Shepherd Dog - German
31,142 reports · 430.0% death rate
Chihuahua
30,657 reports · 420.0% death rate
Frequently Asked Questions
How many FDA adverse event reports involve Kuvasz? ▼
There are 24 adverse event reports involving Kuvasz in the FDA database, with 2 reports involving death (830.0% death rate). Kuvasz ranks #342 by report volume.
What are the most common adverse reactions reported for Kuvasz? ▼
The most commonly reported adverse reactions for Kuvasz are Vomiting (5 reports), Other abnormal test result NOS (5 reports), Anorexia (4 reports), Lack of efficacy (endoparasite) - heartworm (4 reports), Lethargy (see also Central nervous system depression in 'Neurological') (3 reports).
What drugs are most frequently associated with Kuvasz adverse events? ▼
The drugs most frequently referenced in Kuvasz adverse event reports are Fluralaner Chew Tablets (4 reports), Milbemycin Oxime + Spinosad (3 reports), Trilostane (2 reports), Moxidectin (2 reports), Carprofen (2 reports).
What is the average age of Kuvasz in adverse event reports? ▼
The average age of Kuvasz at the time of adverse event reports is 6.4 years, with an average weight of 41.1 kg (90.6 lbs).
Does a high number of adverse event reports mean Kuvasz is unhealthy? ▼
No. FDA adverse event reports are voluntarily submitted and do not prove causation. Popular breeds with more veterinary visits tend to have more reports. The data reflects reporting patterns, not actual incidence rates. Always consult a veterinarian for health decisions.
Where does this Kuvasz safety data come from? ▼
All data comes from the FDA Center for Veterinary Medicine's adverse event reporting system. Pet owners, veterinarians, and manufacturers voluntarily submit reports about adverse events potentially linked to animal drugs and other products.
Guides & Resources
Understanding Adverse Events
What FDA reports are and how they are collected
Breed-Specific Risks
Why some breeds appear in more adverse event reports
Pet Medication Safety
Evaluating medication risks using FDA data
Most Reported Medications
Drugs that appear most in adverse event reports
How FDA CVM Tracks Events
The reporting process and database limitations
Related Data Sources
Data Sources & Methodology
Adverse event data sourced from the FDA Center for Veterinary Medicine via the openFDA Animal & Veterinary Adverse Events API. Reports are voluntarily submitted by pet owners, veterinarians, and product manufacturers.
Kuvasz ranks #342 by total report volume. Death rate (830.0%) reflects the proportion of reports involving death and should not be interpreted as a breed-specific mortality rate. Reporting biases, breed popularity, and veterinary access all influence report counts.
Read our methodology — how this data is sourced, computed, and verified.
Related
Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial